AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32639409 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline median galectin-3 level of 21.1 ng/mL (interquartile range, 17.0-27.2)
Number of subjects: 561
Study 32639409 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3 levels in the highest tertile
Number of subjects: 561
Study 32639409 — intervention group
Group type: EXPERIMENTAL
Intervention: KTR with systolic blood pressure ≥140 mmHg
Number of subjects: 561
Study 32639409 — intervention group
Group type: EXPERIMENTAL
Intervention: KTR with smoking history
Number of subjects: 561
Study 32639484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive speech treatment targeting voice (16 1-hour sessions/1 month)
Number of subjects: 64
Study 32639484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive speech treatment targeting articulation (16 1-hour sessions/1 month)
Number of subjects: 64
Study 32639484 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (no treatment)
Number of subjects: 64
Study 32639485 — intervention group
Group type: EXPERIMENTAL
Intervention: AS04-HPV-16/18
Number of subjects: 546
Study 32639485 — intervention group
Group type: COMPARATOR
Intervention: 4vHPV
Number of subjects: 546
Study 32639845 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete macroscopic excision (CME) in 1,172 patients (77%)
Number of subjects: 1531
Study 32639845 — intervention group
Group type: COMPARATOR
Intervention: Incomplete macroscopic resection (IME) in 359 patients (23%)
Number of subjects: 1531
Study 32640200 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS)
Number of subjects: 33
Study 32640200 — intervention group
Group type: COMPARATOR
Intervention: Histologic and cytologic typing
Number of subjects: 33
Study 32640370 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 32640370 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 32640944 — intervention group
Group type: EXPERIMENTAL
Intervention: Utility-Weighted Modified Rankin Scale (UW-mRS) scores derived from linear regression
Number of subjects: 22946
Study 32640944 — intervention group
Group type: EXPERIMENTAL
Intervention: UW-mRS scores as a continuous variable
Number of subjects: 22946
Study 32640944 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under receiver operator characteristic curves based on EQ-5D utility values
Number of subjects: 22946
Study 32640944 — intervention group
Group type: EXPERIMENTAL
Intervention: Misclassification matrix
Number of subjects: 22946
Study 32641009 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Individual Placement and Support (IPS) intervention
Number of subjects: 0
Study 32641032 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based adherence clubs
Number of subjects: 129
Study 32641032 — intervention group
Group type: COMPARATOR
Intervention: Local primary health care clinic (PHC)
Number of subjects: 129
Study 32641032 — intervention group
Group type: EXPERIMENTAL
Intervention: Both adherence clubs and PHC
Number of subjects: 129
Study 32641071 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran (0.3 mg/kg intravenously every 3 weeks)
Number of subjects: 27
Study 32641131 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% polihexanide solution used for catheter irrigation on five consecutive days
Number of subjects: 15
Study 32641261 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks (Q2W) for ≤ 24 months or until confirmed progression/unacceptable toxicity
Number of subjects: 97
Study 32641261 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks (Q2W)
Number of subjects: 97
Study 32641418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial blood protein expression
Number of subjects: 25
Study 32641418 — intervention group
Group type: EXPERIMENTAL
Intervention: Endopeptidase
Number of subjects: 25
Study 32641418 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholipid transfer protein (PLTP)
Number of subjects: 25
Study 32641418 — intervention group
Group type: EXPERIMENTAL
Intervention: Uromodulin (UMOD)
Number of subjects: 25
Study 32641418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ficolin-2 (FCN2)
Number of subjects: 25
Study 32641418 — intervention group
Group type: EXPERIMENTAL
Intervention: C-C motif chemokine 19 (CCL19)
Number of subjects: 25
Study 32641418 — intervention group
Group type: EXPERIMENTAL
Intervention: C-C motif chemokine 20 (CCL20)
Number of subjects: 25
Study 32641418 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 21
Number of subjects: 25
Study 32641418 — intervention group
Group type: EXPERIMENTAL
Intervention: C-C motif chemokine (CCL23)
Number of subjects: 25
Study 32641862 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent palbociclib
Number of subjects: 196
Study 32642149 — intervention group
Group type: EXPERIMENTAL
Intervention: AG NPP709
Number of subjects: 30
Study 32642592 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Huayu (FZHY) tablets and entecavir
Number of subjects: 350
Study 32642704 — intervention group
Group type: EXPERIMENTAL
Intervention: Marizomib (MRZ)
Number of subjects: 3
Study 32642704 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (BTZ)
Number of subjects: 3
Study 32642704 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib (CFZ)
Number of subjects: 3
Study 32642768 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous rhythm monitoring (implantable loop recorder or pacemaker) for 6 months
Number of subjects: 202
Study 32642992 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-EGFRI 18
Number of subjects: 124
Study 32643012 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal approach for US-guided axillary vein catheterization (AVC)
Number of subjects: 198
Study 32643012 — intervention group
Group type: COMPARATOR
Intervention: Distal approach for US-guided axillary vein catheterization (AVC)
Number of subjects: 198
Study 32643100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (US) during catheter insertion
Number of subjects: 3029
Study 32643100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (US) after adjustment for confounders
Number of subjects: 3029
Study 32643100 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin colonization at catheter removal
Number of subjects: 3029
Study 32643995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusions (6 infusions over 2 weeks)
Number of subjects: 13
Study 32644197 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) RNFL thickness measurements
Number of subjects: 70
Study 32644197 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography measurements
Number of subjects: 70
Study 32644197 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal assessment of RNFL thickness
Number of subjects: 70
Study 32644818 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor/Ivacaftor
Number of subjects: 0
Study 32645016 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadraciclib (CYC065)
Number of subjects: 0
Study 32645016 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadraciclib (CYC065) in combination with BCL2 inhibitors (e.g., venetoclax)
Number of subjects: 0
Study 32645016 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadraciclib
Number of subjects: 0
Study 32645113 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers
Number of subjects: 594
Study 32645113 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about dying
Number of subjects: 594
Study 32645113 — intervention group
Group type: EXPERIMENTAL
Intervention: Unspecified concerns
Number of subjects: 594
Study 32645113 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall concerns
Number of subjects: 594
Study 32645113 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of disease concern
Number of subjects: 594
Study 32645113 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional decline concern
Number of subjects: 594
Study 32645113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dying concern
Number of subjects: 594
Study 32645153 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitors of the renin-angiotensin-aldosterone system
Number of subjects: 0
Study 32645153 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32645282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg orally once daily in 28-day cycles until disease progression or unacceptable toxicity
Number of subjects: 68
Study 32645282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 68
Study 32645640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (600 mg treatment cycles at week 0, 24, 48, 72)
Number of subjects: 55
Study 32645640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (600 mg treatment cycles)
Number of subjects: 55
Study 32646305 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography imaging of nonculprit lesions
Number of subjects: 93
Study 32646305 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive nonculprit lesions
Number of subjects: 93
Study 32646305 — intervention group
Group type: COMPARATOR
Intervention: Nonobstructive lesions
Number of subjects: 93
Study 32646369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted endoscopy (CAE)
Number of subjects: 102
Study 32646369 — intervention group
Group type: COMPARATOR
Intervention: Standard forward-viewing endoscopy (FVE)
Number of subjects: 102
Study 32646369 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopists
Number of subjects: 102
Study 32646574 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cardioversion without anticoagulation
Number of subjects: 0
Study 32646588 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) intravenously at the end of the endometriosis resection
Number of subjects: 21
Study 32646955 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI) assessment of white matter integrity in ALS patients
Number of subjects: 66
Study 32646955 — intervention group
Group type: COMPARATOR
Intervention: Diffusion tensor imaging (DTI) assessment of white matter integrity in healthy controls
Number of subjects: 66
Study 32646955 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of fast vs slow progression in ALS patients
Number of subjects: 66
Study 32647053 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study 32647053 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study 32647531 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple extract (AE, 2.0 g)
Number of subjects: 72
Study 32647531 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulberry fruit extract (MFE, 1.5 g)
Number of subjects: 72
Study 32647531 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulberry leaf extract (MLE, 1.0 g)
Number of subjects: 72
Study 32647531 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderberry extract (EE, 2.0 g)
Number of subjects: 72
Study 32647531 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric extract (TE, 0.18 g)
Number of subjects: 72
Study 32647531 — intervention group
Group type: EXPERIMENTAL
Intervention: White bean extract (WBE, 3.0 g)
Number of subjects: 72
Study 32647531 — intervention group
Group type: EXPERIMENTAL
Intervention: AE + TE
Number of subjects: 72
Study 32647531 — intervention group
Group type: EXPERIMENTAL
Intervention: EE + TE
Number of subjects: 72
Study 32647531 — intervention group
Group type: COMPARATOR
Intervention: Control (rice porridge with ~50 g available carbohydrate)
Number of subjects: 72
Study 32647975 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide (0.035 mg/kg intravenously)
Number of subjects: 11
Study 32648087 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic approaches targeting the NLRP3 inflammasome and its downstream signaling cascade
Number of subjects: 0
Study 32648087 — intervention group
Group type: COMPARATOR
Intervention: NLRP3 inflammasome
Number of subjects: 0
Study 32648108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 4859
Study 32648108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 4859
Study 32648108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin (both doses)
Number of subjects: 4859
Study 32648108 — intervention group
Group type: COMPARATOR
Intervention: Non-ertugliflozin
Number of subjects: 4859
Study 32648205 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Electrical Neuromodulation (REN)
Number of subjects: 38
Study 32648248 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 367
Study 32648303 — intervention group
Group type: EXPERIMENTAL
Intervention: 500-mg ivosidenib in participants with mild hepatic impairment
Number of subjects: 33
Study 32648959 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 5443
Study 32649004 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant bevacizumab (5 mg/kg) with modified FOLFOX7 (oxaliplatin 85 mg/m2) for six cycles
Number of subjects: 17
Study 32649037 — intervention group
Group type: EXPERIMENTAL
Intervention: Supersaturated oxygen (SSO) therapy for 60 minutes
Number of subjects: 100
Study 32649498 — intervention group
Group type: EXPERIMENTAL
Intervention: Candy Cane
Number of subjects: 138
Study 32649498 — intervention group
Group type: COMPARATOR
Intervention: Boot Stirrups
Number of subjects: 138
Study 32649866 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplant cyclophosphamide as graft-versus-host disease (GVHD) prophylaxis and an optimized ART strategy including enfuvirtide.
Number of subjects: 9
Study 32649866 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplant cyclophosphamide and optimized ART strategy.
Number of subjects: 9
Study 32649919 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumour cells (CTCs) detection using the isolation by size of epithelial tumour cell technique (ISET)
Number of subjects: 614
Study 32649919 — intervention group
Group type: COMPARATOR
Intervention: Low-dose chest CT (LDCT) screening
Number of subjects: 614
Study 32650305 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported symptoms of SARS-CoV-2 infection (myalgia, olfactory and taste disorders, cough, fever)
Number of subjects: 4392
Study 32650305 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported symptoms in nontested population
Number of subjects: 4392
Study 32650731 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIDE85+ study intervention including cognitive evaluations (CERAD, Trail Making Test-A, Letter-Digit Substitution Test, Clinical Dementia Rating, Activities of Daily Living) and assessments of physical health status, psychosocial wellbeing, and blood biomarkers relevant for dementia and ageing.
Number of subjects: 2900
Study 32650734 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective colorectal surgery
Number of subjects: 0
Study 32650734 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency abdominal surgery
Number of subjects: 0
Study 32650734 — intervention group
Group type: EXPERIMENTAL
Intervention: General medicine with acute bacterial infections
Number of subjects: 0
Study 32650734 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcome Measures Information System and Short Physical Performance Battery
Number of subjects: 0
Study 32650781 — intervention group
Group type: EXPERIMENTAL
Intervention: French WHOQOL-HIV BREF
Number of subjects: 586
Study 32651242 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided focused ultrasound (MRgFUS) thalamotomy
Number of subjects: 94
Study 32651241 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 0
Study 32651241 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss in people with obesity
Number of subjects: 0
Study 32651241 — intervention group
Group type: COMPARATOR
Intervention: Lean healthy people
Number of subjects: 0
Study 32651674 — intervention group
Group type: EXPERIMENTAL
Intervention: JAAM-DIC score
Number of subjects: 582
Study 32651674 — intervention group
Group type: EXPERIMENTAL
Intervention: ISTH overt-DIC score
Number of subjects: 582
Study 32651674 — intervention group
Group type: EXPERIMENTAL
Intervention: SIC score
Number of subjects: 582
Study 32651674 — intervention group
Group type: COMPARATOR
Intervention: SIC score combined with JAAM-DIC score
Number of subjects: 582
Study 32651674 — intervention group
Group type: COMPARATOR
Intervention: SIC score combined with ISTH overt-DIC score
Number of subjects: 582
Study 32651887 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release naltrexone treatment starting in the week prior to release from prison
Number of subjects: 100
Study 32651887 — intervention group
Group type: EXPERIMENTAL
Intervention: Training to use naloxone rescue kits and provision of nasal naloxone at release
Number of subjects: 100
Study 32651887 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing support from a certified recovery mentor for 6 months post-release
Number of subjects: 100
Study 32651887 — intervention group
Group type: COMPARATOR
Intervention: Comparison group of females released from prison during the study period
Number of subjects: 100
Study 32651996 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapies prescribed after percutaneous coronary intervention
Number of subjects: 0
Study 32651996 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32652034 — intervention group
Group type: EXPERIMENTAL
Intervention: Low n-6:n-3 PUFA ratio diet (4:1) for 12 weeks
Number of subjects: 20
Study 32652442 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib (3 mg/kg)
Number of subjects: 0
Study 32652442 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Pamiparib with Temozolomide (TMZ)
Number of subjects: 0
Study 32652442 — intervention group
Group type: COMPARATOR
Intervention: Pamiparib
Number of subjects: 0
Study 32653053 — intervention group
Group type: EXPERIMENTAL
Intervention: Margetuximab 15 mg/kg plus pembrolizumab 200 mg intravenously every 3 weeks (recommended phase 2 dose)
Number of subjects: 95
Study 32653053 — intervention group
Group type: EXPERIMENTAL
Intervention: Margetuximab 10 mg/kg plus pembrolizumab 200 mg intravenously every 3 weeks (dose-escalation phase)
Number of subjects: 95
Study 32653053 — intervention group
Group type: EXPERIMENTAL
Intervention: Margetuximab plus pembrolizumab
Number of subjects: 95
Study 32653445 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient calorie intake (<90% of metabolic needs)
Number of subjects: 57
Study 32653445 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient calorie intake
Number of subjects: 57
Study 32653622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib (4 mg, oral, weekly for 4 doses from days +60 to +90)
Number of subjects: 57
Study 32653622 — intervention group
Group type: COMPARATOR
Intervention: CIBMTR controls (matched contemporaneous controls)
Number of subjects: 57
Study 32654183 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (no intervention reported, observational study)
Number of subjects: 304
Study 32654363 — intervention group
Group type: EXPERIMENTAL
Intervention: Open radical prostatectomy (ORP)
Number of subjects: 500
Study 32654363 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical prostatectomy (RARP)
Number of subjects: 500
Study 32654363 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic lymph node dissection (PLND)
Number of subjects: 500
Study 32654363 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage pT3b disease
Number of subjects: 500
Study 32654363 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative opioid use (inpatient)
Number of subjects: 500
Study 32654363 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative opioid use (outpatient)
Number of subjects: 500
Study 32654558 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 13764
Study 32654558 — intervention group
Group type: COMPARATOR
Intervention: No beta-blocker therapy
Number of subjects: 13764
Study 32654872 — intervention group
Group type: EXPERIMENTAL
Intervention: Valiant Captivia thoracic stent graft (Medtronic Inc)
Number of subjects: 50
Study 32655854 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose scopolamine
Number of subjects: 66
Study 32655854 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose scopolamine
Number of subjects: 66
Study 32655854 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline i.m.)
Number of subjects: 66
Study 32655940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 1.25 mg (0.05 ml) bevacizumab followed by phacoemulsification, pars plana vitrectomy (PPV) including panretinal photocoagulation (PRP), and trabeculectomy with mitomycin C (MMC)
Number of subjects: 12
Study 32656160 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of candesartan (16 mg) and amlodipine (10 mg)
Number of subjects: 39
Study 32656160 — intervention group
Group type: COMPARATOR
Intervention: Coadministration of individual formulations of candesartan (16 mg) and amlodipine (10 mg)
Number of subjects: 39
Study 32657017 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatofluoroscopy
Number of subjects: 476
Study 32657505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sebelipase alfa (1.0 or 3.0 mg/kg every other week) for up to 5 years
Number of subjects: 8
Study 32657973 — intervention group
Group type: EXPERIMENTAL
Intervention: Betrixaban or Rivaroxaban
Number of subjects: 3
Study 32657973 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 3
Study 32658300 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment with urinary dipstick and creatinine at admission, followed by urinary sediment and quantification of albuminuria if positive.
Number of subjects: 0
Study 32658300 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory treatment discussed with a nephrologist.
Number of subjects: 0
Study 32658300 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of ACEi/ARBs treatment if possible.
Number of subjects: 0
Study 32658601 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal gut microbiota
Number of subjects: 117
Study 32658601 — intervention group
Group type: EXPERIMENTAL
Intervention: Meconium microbiota of very preterm neonates (born after 28 gestational weeks)
Number of subjects: 117